Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib + Radiation + Temozolomide for Newly Diagnosed Glioblastoma
NCT06991101Phase 2Recruiting
- Sponsor
- Baptist Health South Florida
- Start
- Dec 2025
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in glioblastoma (GBM), sponsored by Baptist Health South Florida. Started Dec 2025; status: recruiting.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06991101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06991101.